Stock comparison
Royalty Pharma
Vir Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
VIR
Vir Biotechnology
Market cap
$1.55B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RPRX | VIR | Winner |
|---|---|---|---|
| Warren Buffett | 66C | 20F | RPRX |
| Benjamin Graham | 84A | 37D | RPRX |
| Philip Fisher | 65C | 31F | RPRX |
| Peter Lynch | 60C | 3F | RPRX |
| Joel Greenblatt | 40D | 2F | RPRX |
| Charlie Munger | 68D | 38D | RPRX |
| Terry Smith | 58D | 38D | RPRX |
Side-by-side metrics
| Metric | RPRX | VIR |
|---|---|---|
| Market cap | $23.44B | $1.55B |
| P/E (TTM) | 27.6x | - |
| EV/EBIT | 19.9x | - |
| ROIC (TTM) | 8.43% | -48.49% |
| Gross margin | 99.95% | 2.75% |
| Net margin | 33.91% | -6.76% |
| Revenue CAGR 5y | 0.96% | -49.98% |
| EPS CAGR 5y | 11.83% | - |
| Debt / Equity | 1.3x | 0.1x |
| Dividend yield | 1.72% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RPRX leads on
- ROIC (TTM)8.43%vs -48.49%+117%
- Net margin33.91%vs -6.76%+105%
- Revenue CAGR 5y0.96%vs -49.98%+102%
- Dividend yield1.72%vs 0.0%+100%
VIR leads on
- EV/EBIT-vs 19.9x+114%
- P/E (TTM)-vs 27.6x+111%
- Debt / Equity0.1xvs 1.3x+92%
- Gross margin2.75%vs 99.95%+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.